Haematological toxicity is considered a secondary end point important for graft evaluation -in todays' practice graft evaluation focuses on the primary impact of health economic end points. This report illustrates the benefit of combining CD34 enumeration and demographic as well as disease-related variables in models for individual quality assessment of autografting following high-dose therapy. A total of 24 centres in Scandinavia enrolled 204 patients younger than 67 years who received high-dose therapy with autologous peripheral blood stem cell transplantation. Using the binary Logistic Regression Analysis, the prognostic value of diagnostic demographic variables, therapy and graft-related factors was entered into a multivariate analysis and the final significant models were used to estimate probabilities for acceptable or unacceptable outcome among different patient scenarios. The model that estimated post-transplant efficacy by selected primary end points (time on antibiotics and use of transfusions) includes six independent variables related to sex, age, disease, conditioning, growth factor administration, and graft CD34+ cell number. The model that estimated transplantation-related toxicity by selected secondary end points (time to blood cell recovery) included four independent variables related to age, disease, growth factor administration and graft CD34+ cell number.
High-dose therapy with autologous stem cell transplantation (ASCT) is effective in young patients with haematological malignancies. [1] [2] [3] [4] Recently, survival data from prospective, population-based Nordic studies have been published. 5, 6 Before these studies were initiated in the mid1990s, it was decided to introduce a quality assessment programme for haematopoietic progenitor and stem cell grafts (HPSC). The goal for such a programme was, at the lowest possible cost and resource expenditure, to practice posttransplant supportive care, to reduce graft-related side effects and avoid procedure-related health disadvantages for the patients. Following three workshops on enumeration of CD34+ cells by flow cytometry, [7] [8] [9] a Nordic standard was used including the recommendation to harvest 42 million CD34+ cells/kg bodyweight for supportive autografting. However, this laboratory programme has never been analysed by clinical end points.
Evaluation of specific clinical end points has recently been proposed. 10, 11 In accordance with clinical evaluation of other therapies in medicine (eg chemotherapy), the primary objective is to study efficacy, which in the context of post-transplant supportive care may be defined by, for example, days on antibiotics and transfusions of blood products. Secondary objectives may be to study toxicity, defined by, for example, time to blood cell recovery. Tertiary objectives may be to study safety defined by risk for early relapse or death.
Several studies have documented the influence of CD34 numbers on some of these end points. 10 First, the data suggest an upper optimal limit of stem cell numbers transfused, beyond which further increase is without benefit, and second, a minimal number below which patients are at risk for prolonged time to blood cell recovery. However, questions related to graft quality and numbers of CD34+ cells are an ongoing controversy as other disease and therapy-related variables have been found to be of influence. Consequently, we have estimated prognostic models regarding the shorttime efficacy and toxicity related to reinfusion of autologous HPSC. Our attempt has been to illustrate that an individual probability evaluation may be important for quality assessment of autografting following high-dose therapy.
Material and methods

Patients and treatment
From 1994 to 1997, 24 centres in Denmark, Norway, Finland and Sweden registered 391 patients o67 years.
By evaluation of full datasheets on mobilization, leukapheresis and transplantation, 204 transplanted patients with nonleukaemic diagnosis were selected for this retrospective analysis. The registration sheets have previously been published. 9 The diagnostic criteria, treatment protocol, response criteria and follow-up were based on local principles.
Graft handling and flow cytometry analysis
Peripheral blood stem cell harvest was performed by leukapheresis when blood levels of CD34+ cells exceeded 10-20 000/ml. Leukapheresis was performed using local devices, and procedures like graft handling were carried out before freezing in DMSO. A minimum of 2 Â 10 6 CD34+ cells/kg bodyweight was harvested in one or more daily procedures.
Enumeration of CD34+ cells was performed by flow cytometry as described previously. 9 
Study objectives and end points
Based on the proposal from the EBMT subcommittee on 'quality assessment of autologous stem cell graft', 10 variables were analysed for the influence on binary clinical end points graded as 'acceptable' or 'unacceptable', described in Table 1 . According to the definitions given, the distribution of patients is given as well.
Statistical analysis
The prognostic models were based on the following variables ( Table 2) : patients' sex, age, diagnosis, the conditioning programme, post-transplant growth factor administration and number of reinfused CD34+cells analysed in a binary logistic regression analysis (see below). Different measures of CD34+ cells were used, for example, CD34+ cells per kg patient weight, the average number of CD34+ cells harvested per day (average CD34/days), and the total number harvested (total CD34). Average CD34+ cell number was used in the logistic model. Logistic regression analyses were used to estimate odds ratios for each of the independent variables in the multinominal logistic regression model (MLR). The logarithm of the odds of the independent variable is expressed as a linear combination of parameters.
The multivariate model is given by
From (1), it follows that the model can be rewritten in terms of odds as
Further, the probabilities for the graded categories are given by
Following likelihood ratio testing, explanatory variables were excluded one by one in the multivariate models until no further variables could be excluded (Table 3A , B). The prognostic variables were subsequently used to estimate probability for the outcome (acceptable or unacceptable as defined in Table 1 ) depending on the level of CD34 numbers in the harvested graft (Figures 1 and 2 ). Probability of graded outcome for different patient scenarios were estimated by equations (3) and (4) in combination with estimates given in Tables 3A and B .
Results
Prognostic variables and models for efficacy of stem cell autografting
Analyses of the influence of demographic, disease-related and graft-related variables (Table 2 ) on the graded primary Days on antibiotics and use of transfusions of blood products define efficacy (primary objectives) and the time to blood cell recovery defined toxicity (secondary objectives) in accordance with the proposal from the EBMT subcommittee on 'Quality assessment of autologous stem cell graft'. 10 The number of patients graded with an acceptable or unacceptable outcome is given.
end points identified 6 out of 13 to be of significance (Table 3A) . These were sex, age, high-grade NHL, TBI+Cy, growth factor administration and the graft described by the average CD34+ cell number harvested per day of leukapheresis.
The estimated prognostic model allowed us to simulate the probabilities of obtaining an acceptable outcome depending on varying CD34+ cell numbers reinfused. This is illustrated for different clinical scenarios in Figure 1a -c. The model predicts an increasing risk of an unacceptable outcome when the CD34 number is reduced and a decreasing risk with increased CD34 numbers (Figure 1  a-c) . In terms of odds ratio, the effect of an increase in the mean value of average CD34 is given by equation (3) (see Material and methods) and Table 3A . An increase in average CD34 by 100 Â 10 6 cells results in a calculated odds ratio of 0.9045 with a 95% confidence interval of [0.9045;1]. In other words, the odds of an unacceptable situation decrease by a factor of 0.9045 if the average CD34 + cell numbers increased by 100 Â 10 6 CD34+ cells. To illustrate different patient scenarios the individual probability estimate is shown in Figure 1a for a male, mean age, without high-grade NHL, not conditioned by TBI+Cy, but receiving post-transplant rhG-CSF. Interestingly, the patient who, based on local criteria, received rhG-CSF had a reduced chance of an acceptable outcome compared to a patient receiving no growth factor. In parallel, a male, mean age, suffering from another malignancy than high-grade NHL who did not receive TBI+Cy had a higher probability of obtaining an acceptable outcome compared to a patient with high-grade NHL (Figure 1b) . Finally, a patient receiving TBI+Cy had an increased chance for an acceptable outcome compared to a patient conditioned with any other regimen (Figure 1c ).
Prognostic variables and models for toxicity of autografting
For end points describing 'haematological toxicity', the explanatory variables of importance included age, breast cancer, growth factor administration and average CD34+ cells harvested per day (Table 3B) . Again, the estimated prognostic model predicts chance of an acceptable outcome to depend upon CD34 numbers. An increase in average CD34+ cells by 100 Â 10 6 cells results in a calculated odds ratio of 0.9045 with a 95% confidence interval of [0.82;1]. In other words, the odds of an unacceptable situation decrease by a factor of 0.9045 if CD34+ cells increase to 100 Â 10 6 . Again, the relative influence of other variables is shown for an average patient receiving post-transplant The study consisted of a highly selected patient cohort of non-leukaemic diseases, autotransplanted in the Nordic area during 1996-98. (Figure 2a ) with or without breast cancer (Figure 2b ). In contrast to the primary end points, rhG-CSF administration increased the chance of an acceptable time to blood cell recovery among patients with other diseases than breast cancer (Figure 2a ). For patients with breast cancer, the chance of a successful outcome was higher even without growth factor administration ( Figure 2b ).
The CD34 number harvested and reinfused correlate to blood CD34 level
The major impact of the graft CD34 numbers raised the question whether this reflects the grade of blood mobilization following priming. Analyses of mobilization capacity reflected by the measured maximum blood CD34 levels revealed a significant correlation (data not given, see Johnsen et al 9 ). Inclusion of the maximum blood CD34 level in the statistical analysis was shown to be of significance, but still so was the average number of CD34+ cells per day harvested (data not given).
Discussion
This analysis is based on data generated from a graft quality assessment programme [7] [8] [9] and recently proposed objectives, end points and grading of post-transplant supportive therapy, and toxicity. 10 Important issues as normal day clinical practice and biological knowledge are taken into consideration in the definition of acceptable and unacceptable outcome in the grading system. It has to be stressed that the end points registered in this retrospective multicentre study may be a consequence of different clinical practice concerning post-transplant transfusions and antibiotic strategies. However, all centres included in the analyses performed more than 20 transplantations per year, indicating significant experience in supportive care. At the time of data sampling, no recommendation was given and the outcome could reflect a variation in decision-making in daily patient care. Consequently, the variables analysed are very likely influenced not only by biology, but also by clinical practice. A time-dependent grading of efficacy is proposed by length of antibiotic treatment together with transfusion therapy delineating a grading with acceptable supportive care in patients o7 days on antibiotics and with an minor needs for transfusion therapy. In contrast, the group of patients with an unacceptable outcome were treated 47 days with continuous antibiotics or more than one transfusion of a batch of platelets or 2 U of RBC. When it comes to toxicity, the proposed grading analysed time to blood cell recovery and described two groups of patients based on time to ANC and platelet, reaching 0.5 Â 10 9 /l and 20.000 Â 10 9 /l, respectively. An appropriate statistical method identified six factors independently affecting the primary end points including sex, age, high-grade NHL, TBI+Cy conditioning, growth factor administration and the number of CD34+ cells reinfused (Table 3A) . For the secondary end points, four variables were of importance including age, breast cancer, growth factor administration and the CD34 number reinfused (Table 3B) .
The results of this analysis allowed us to estimate predictive models depending upon the relative effect of each variable (Table 3A and Figures 1 and 2 ). It is of major interest that patients treated with rhG-CSF had a reduced chance of minimal antibiotic or transfusion therapy when compared to no rhG-CSF treatment (Figure 1a) . However, the beneficial effect on time to blood cell recovery was obvious (Figure 2a ). Most likely, this contradiction is a consequence of an 'unknown' clinical practice selecting a group of patients considered at 'low' risk for inappropriate autografting. Whether this is grounded on knowledge about previous therapy or disease history is unknown and needs to be addressed, as several randomized trials have documented rhG-CSF effective. [12] [13] [14] The disease type is found to be of importance for 'other malignancies' compared to high-grade NHL patients (Figure 1b) . This is probably a consequence of treating NHL patients in relapse. 3, 4 Breast cancer patients have a faster blood cell recovery, compared to 'other malignancies' (Figure 2b) , which may reflect the fact that induction therapy has a minor haematotoxic effect. That conditioning with TBI resulted in a high chance of an acceptable supportive outcome is an important observation. The reason is unknown, but may be a consequence of selecting for example, patients not having previous radiotherapy known to affect haematopoiesis.
The generated predictive MLR models included only one variable that may be controlled by pretransplant intervention: the CD34+ cell number harvested. However, it is an open question if an extension of days of apheresis would increase the graft quality, as it may decrease the average CD34 number harvested per day. Future studies need to evaluate such questions, especially whether patients who had a sufficient number of CD34+ cells harvested would benefit from (1) increasing the total number and decreasing the average number per day of harvest or (2) more potent priming regimen increasing blood levels before harvest. If such questions are answered in the future, individual assessment may allow the clinicians to intervene before the high-dose therapy is initiated. However, the predictive value of such an estimate is of major importance. In our analyses, the estimated primary model classifies the 'acceptable' category correct in 77% of all observations, but the 'unacceptable' category is only correct for 55%. The estimated secondary model classifies the 'acceptable' category correctly in 81% of all observations. Again, the category 'unacceptable' is classified correctly at a markedly lower percentage, 57%. The predictive value was based on the actual data set and should be analysed prospectively in future studies.
The aim with the actual analyses was to illustrate that an individual probability evaluation may be an important step in assessment of autografting including the high-dose therapy.
The present report describes the strategy and highlights problems to be solved in future multicentre studies. Several limitations to the study should be recognized. It is retrospective and concerns a heterogeneous disease population receiving different induction therapy, mobilization regimens as well as high-dose therapy. The models should include health economical evaluations and consequently also include time in hospital with well-defined descriptions of criteria for admission and discharge of patients. Finally, although this analysis identified several significant variables, including CD34+ cell numbers, we cannot exclude the existence of many more important factors.
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